Nexus Drug Patent Portfolio
Nexus owns 1 orange book drug protected by 5 US patents Given below is the list of Nexus's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11090278 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same | 16 May, 2040 | Active |
| US11241400 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same | 16 May, 2040 | Active |
| US11464752 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same | 16 May, 2040 | Active |
| US11478436 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same | 16 May, 2040 | Active |
| US11571398 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same | 16 May, 2040 | Active |
Latest Legal Activities on Nexus's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Nexus.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 Jun, 2023 | US11464752 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 Jun, 2023 | US11241400 |
|
Email Notification
Critical
| 14 Jun, 2023 | US11478436 |
|
Electronic Review
Critical
| 14 Jun, 2023 | US11478436 |
|
Email Notification
Critical
| 14 Jun, 2023 | US11241400 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 Jun, 2023 | US11478436 |
|
Electronic Review
Critical
| 14 Jun, 2023 | US11464752 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 Jun, 2023 | US11090278 (Litigated) |
|
Email Notification
Critical
| 14 Jun, 2023 | US11464752 |
|
Email Notification
Critical
| 14 Jun, 2023 | US11090278 (Litigated) |
|
Electronic Review
Critical
| 14 Jun, 2023 | US11241400 |
|
Electronic Review
Critical
| 14 Jun, 2023 | US11090278 (Litigated) |
|
Electronic Review
Critical
| 13 Jun, 2023 | US11571398 (Litigated) |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 13 Jun, 2023 | US11571398 (Litigated) |
|
Email Notification
Critical
| 13 Jun, 2023 | US11571398 (Litigated) |
Nexus's Family Patents
Nexus drugs have patent protection in a total of 8 countries. It has a significant patent presence in the US with 56.2% of its patents being US patents. Click
below to unlock the full patent family tree.
Nexus Drug List
Given below is the complete list of Nexus's drugs and the patents protecting them.
1. Emerphed
Emerphed is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11090278 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
16 May, 2040
(15 years from now)
| Active |
| US11241400 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
16 May, 2040
(15 years from now)
| Active |
| US11464752 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
16 May, 2040
(15 years from now)
| Active |
| US11478436 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
16 May, 2040
(15 years from now)
| Active |
| US11571398 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
16 May, 2040
(15 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Emerphed's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List